Abstract
| Language | English |
|---|---|
| Pages | 77-85 |
| Number of pages | 9 |
| Journal | International Journal of Pharmaceutics |
| Volume | 285 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - 2004 |
Fingerprint
Keywords
- niosomes
- glucose
- vasoactive intestinal peptide
- brain delivery
- blood–brain barrier
- pharmacology
- biomedical sciences
Cite this
}
Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. / Dufès, Christine; Gaillard, Frédéric; Uchegbu, I.F.; Schätzlein, Andreas G.; Olivier, Jean-Christophe; Muller, Jean-Marc.
In: International Journal of Pharmaceutics, Vol. 285, No. 1-2, 2004, p. 77-85.Research output: Contribution to journal › Article
TY - JOUR
T1 - Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain
AU - Dufès,Christine
AU - Gaillard,Frédéric
AU - Uchegbu,I.F.
AU - Schätzlein,Andreas G.
AU - Olivier,Jean-Christophe
AU - Muller,Jean-Marc
PY - 2004
Y1 - 2004
N2 - The aim of this study was to evaluate glucose-bearing niosomes as a brain targeted delivery system for the vasoactive intestinal peptide (VIP). To this end, VIP/125I-VIP-loaded glucose-bearing niosomes were intravenously injected to mice. Brain uptake was determined by measuring the radioactivity of 125I-labeled VIP using gamma-counting, after intravenous administration of VIP in solution or encapsulated in glucose-bearing niosomes or in control niosomes. VIP integrity was assessed by reversed-phase HPLC analysis of brain extracts. Distribution of 125I-VIP derived radioactivity was examined from serial brain slices. HPLC analysis confirmed the presence of intact VIP in brain after administration of VIP-loaded niosomes, but not after administration of VIP solution. Encapsulation within glucose-bearing niosomes mainly allowed a significantly higher VIP brain uptake compared to control niosomes (up to 86%, 5min after treatment). Brain distribution of intact VIP after injection of glucose-bearing niosomes, indicated that radioactivity was preferentially located in the posterior and the anterior parts of the brain, whereas it was homogeneously distributed in the whole brain after the administration of control vesicles. In conclusion, this novel vesicular formulation of VIP delivers intact VIP to particular brain regions in mice. Glucose-bearing vesicles might be therefore a novel tool to deliver drugs across the blood-brain barrier (BBB).
AB - The aim of this study was to evaluate glucose-bearing niosomes as a brain targeted delivery system for the vasoactive intestinal peptide (VIP). To this end, VIP/125I-VIP-loaded glucose-bearing niosomes were intravenously injected to mice. Brain uptake was determined by measuring the radioactivity of 125I-labeled VIP using gamma-counting, after intravenous administration of VIP in solution or encapsulated in glucose-bearing niosomes or in control niosomes. VIP integrity was assessed by reversed-phase HPLC analysis of brain extracts. Distribution of 125I-VIP derived radioactivity was examined from serial brain slices. HPLC analysis confirmed the presence of intact VIP in brain after administration of VIP-loaded niosomes, but not after administration of VIP solution. Encapsulation within glucose-bearing niosomes mainly allowed a significantly higher VIP brain uptake compared to control niosomes (up to 86%, 5min after treatment). Brain distribution of intact VIP after injection of glucose-bearing niosomes, indicated that radioactivity was preferentially located in the posterior and the anterior parts of the brain, whereas it was homogeneously distributed in the whole brain after the administration of control vesicles. In conclusion, this novel vesicular formulation of VIP delivers intact VIP to particular brain regions in mice. Glucose-bearing vesicles might be therefore a novel tool to deliver drugs across the blood-brain barrier (BBB).
KW - niosomes
KW - glucose
KW - vasoactive intestinal peptide
KW - brain delivery
KW - blood–brain barrier
KW - pharmacology
KW - biomedical sciences
U2 - 10.1016/j.ijpharm.2004.07.020
DO - 10.1016/j.ijpharm.2004.07.020
M3 - Article
VL - 285
SP - 77
EP - 85
JO - International Journal of Pharmaceutics
T2 - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
IS - 1-2
ER -